Lymphangitis carcinomatosa

WikiDoc Resources for Lymphangitis carcinomatosa
Articles
Most recent articles on Lymphangitis carcinomatosa Most cited articles on Lymphangitis carcinomatosa Review articles on Lymphangitis carcinomatosa Articles on Lymphangitis carcinomatosa in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lymphangitis carcinomatosa Images of Lymphangitis carcinomatosa Photos of Lymphangitis carcinomatosa Podcasts & MP3s on Lymphangitis carcinomatosa Videos on Lymphangitis carcinomatosa
Evidence Based Medicine
Cochrane Collaboration on Lymphangitis carcinomatosa Bandolier on Lymphangitis carcinomatosa TRIP on Lymphangitis carcinomatosa
Clinical Trials
Ongoing Trials on Lymphangitis carcinomatosa at Clinical Trials.gov Trial results on Lymphangitis carcinomatosa Clinical Trials on Lymphangitis carcinomatosa at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lymphangitis carcinomatosa NICE Guidance on Lymphangitis carcinomatosa NHS PRODIGY Guidance FDA on Lymphangitis carcinomatosa CDC on Lymphangitis carcinomatosa
Books
Books on Lymphangitis carcinomatosa
News
Lymphangitis carcinomatosa in the news Be alerted to news on Lymphangitis carcinomatosa News trends on Lymphangitis carcinomatosa
Commentary
Blogs on Lymphangitis carcinomatosa
Definitions
Definitions of Lymphangitis carcinomatosa
Patient Resources / Community
Patient resources on Lymphangitis carcinomatosa Discussion groups on Lymphangitis carcinomatosa Patient Handouts on Lymphangitis carcinomatosa Directions to Hospitals Treating Lymphangitis carcinomatosa Risk calculators and risk factors for Lymphangitis carcinomatosa
Healthcare Provider Resources
Symptoms of Lymphangitis carcinomatosa Causes & Risk Factors for Lymphangitis carcinomatosa Diagnostic studies for Lymphangitis carcinomatosa Treatment of Lymphangitis carcinomatosa
Continuing Medical Education (CME)
CME Programs on Lymphangitis carcinomatosa
International
Lymphangitis carcinomatosa en Espanol Lymphangitis carcinomatosa en Francais
Business
Lymphangitis carcinomatosa in the Marketplace Patents on Lymphangitis carcinomatosa
Experimental / Informatics
List of terms related to Lymphangitis carcinomatosa

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Historical Perspective

• Lymphangitis carcinomatosa was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of lymphangitis carcinomatosa.
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose lymphangitis carcinomatosa.

Classification

• Lymphangitis carcinomatosa may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of lymphangitis carcinomatosa include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of lymphangitis carcinomatosa is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of lymphangitis carcinomatosa, involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of lymphangitis carcinomatosa.
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of lymphangitis carcinomatosa.

Causes

• Lymphangitis carcinomatosa may be caused by either [cause1], [cause2], or [cause3].
• Lymphangitis carcinomatosa is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for lymphangitis carcinomatosa.

Differentiating lymphangitis carcinomatosa from other Diseases

• Lymphangitis carcinomatosa must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of lymphangitis carcinomatosa is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of lymphangitis carcinomatosa was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop lymphangitis carcinomatosa.

• Lymphangitis carcinomatosa is more commonly observed among patients aged [age range] years old.
• Lymphangitis carcinomatosa is more commonly observed among [elderly patients/young patients/children].

Gender

• Lymphangitis carcinomatosa affects men and women equally.

• [Gender 1] are more commonly affected with lymphangitis carcinomatosa than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for lymphangitis carcinomatosa.

• Lymphangitis carcinomatosa usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop lymphangitis carcinomatosa.

Risk Factors

• Common risk factors in the development of lymphangitis carcinomatosa are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with lymphangitis carcinomatosa remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with lymphangitis carcinomatosa may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of lymphangitis carcinomatosa include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with lymphangitis carcinomatosa is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of lymphangitis carcinomatosa is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• Lymphangitis carcinomatosa is usually asymptomatic.
• Symptoms of lymphangitis carcinomatosa may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with lymphangitis carcinomatosa usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with lymphangitis carcinomatosa.

• A [positive/negative] [test name] is diagnostic of lymphangitis carcinomatosa.
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of lymphangitis carcinomatosa.
• Other laboratory findings consistent with the diagnosis of lymphangitis carcinomatosa include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with lymphangitis carcinomatosa.

• [Imaging study 1] is the imaging modality of choice for lymphangitis carcinomatosa.
• On [imaging study 1], lymphangitis carcinomatosa is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• Lymphangitis carcinomatosa may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for lymphangitis carcinomatosa; the mainstay of therapy is supportive care.

• The mainstay of therapy for lymphangitis carcinomatosa is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for lymphangitis carcinomatosa.
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of lymphangitis carcinomatosa.
• [Surgical procedure] can only be performed for patients with [disease stage] lymphangitis carcinomatosa.

Prevention

• There are no primary preventive measures available for lymphangitis carcinomatosa.

• Effective measures for the primary prevention of lymphangitis carcinomatosa include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with lymphangitis carcinomatosa are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].